BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

...SE, which launched in October, is developing multivalent single-domain antibodies for COVID-19. A team led by University of Bonn...
...myotonica-protein kinaseSARS-CoV-2 S – SARS-CoV-2 spike protein TFRC (TFR) (CD71) – Transferrin receptor Danielle Golovin Dyne Therapeutics Inc. University of Basel University of Bonn Karolinska...
BioCentury | Jul 31, 2020
Distillery Therapeutics

ADORA2B agonism for obesity and aging-induced sarcopenia

...published online June 25, 2020 doi:10.1016/j.cmet.2020.06.006 CONTACT: Alexander Pfeifer, University of Bonn, Bonn, Germany email: alexander.pfeifer@uni-bonn.de Claire Quang University of Bonn Adenosine...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Inhibiting SPK2 to treat Middle East respiratory syndrome

...Munich, Germany email: theorein@psych.mpg.de CONTACT: Nils C. Gassen, Max Planck Institute of Psychiatry, Munich, Germany; University of Bonn...
BioCentury | Jul 20, 2018
Financial News

IFM launches subsidiary with $31M series A

..."well underway." In December, a study published in Nature led by IFM Tre co-founder and University of Bonn...
BioCentury | Jul 19, 2018
Financial News

IFM launches subsidiary with $31M series A

..."well underway." In December, a study published in Nature led by IFM Tre co-founder and University of Bonn...
...“BMS Expanding I-O Portfolio Through IFM Acquistion” ). Jaime De Leon Bristol-Myers Squibb Co. IFM Therapeutics Inc. IFM Therapeutics LLC University of Bonn NLR...
BioCentury | Feb 21, 2018
Distillery Techniques

Drug delivery

...Famulok, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany email: m.famulok@uni-bonn.de Hongjiang Li Caris Life Sciences Inc. University of Bonn c-Met...
BioCentury | Jan 19, 2018
Strategy

After amyloid

...the field. An inflammasome target for AD was recently identified by a team from the University of Bonn...
...extracellular environment and further triggers more and more β amyloid aggregation,” said Eicke Latz, a University of Bonn...
...Altos, Calif. Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland Tiaki Therapeutics, Cambridge, Mass. University of Bonn...
BioCentury | Jan 4, 2018
Distillery Therapeutics

Neurology

...Venegas, C. et al. Nature ; published online Dec. 20, 2017 doi:10.1038/nature25158 CONTACT: Michael Heneka, University of Bonn...
BioCentury | Dec 22, 2017
Preclinical News

New inflammasome target for early intervention in AD

...disease, offering an earlier intervention than targeting established amyloid plaques. The study was led by University of Bonn...
...treat chronic inflammatory conditions (see BioCentury Innovations, Aug. 10 ) . Allison Johnson Bristol-Myers Squibb Co. IFM Therapeutics LLC University of Bonn NLR...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Cancer

...Tüting, same affiliation as above email: thomas.tueting@med.ovgu.de CONTACT: Michael Hölzel, University of Bonn, Bonn, Germany email: michael.hoelzel@ukbonn.de Mark Zipkin capmatinib University of Bonn c-Met...
Items per page:
1 - 10 of 71
BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

...SE, which launched in October, is developing multivalent single-domain antibodies for COVID-19. A team led by University of Bonn...
...myotonica-protein kinaseSARS-CoV-2 S – SARS-CoV-2 spike protein TFRC (TFR) (CD71) – Transferrin receptor Danielle Golovin Dyne Therapeutics Inc. University of Basel University of Bonn Karolinska...
BioCentury | Jul 31, 2020
Distillery Therapeutics

ADORA2B agonism for obesity and aging-induced sarcopenia

...published online June 25, 2020 doi:10.1016/j.cmet.2020.06.006 CONTACT: Alexander Pfeifer, University of Bonn, Bonn, Germany email: alexander.pfeifer@uni-bonn.de Claire Quang University of Bonn Adenosine...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Inhibiting SPK2 to treat Middle East respiratory syndrome

...Munich, Germany email: theorein@psych.mpg.de CONTACT: Nils C. Gassen, Max Planck Institute of Psychiatry, Munich, Germany; University of Bonn...
BioCentury | Jul 20, 2018
Financial News

IFM launches subsidiary with $31M series A

..."well underway." In December, a study published in Nature led by IFM Tre co-founder and University of Bonn...
BioCentury | Jul 19, 2018
Financial News

IFM launches subsidiary with $31M series A

..."well underway." In December, a study published in Nature led by IFM Tre co-founder and University of Bonn...
...“BMS Expanding I-O Portfolio Through IFM Acquistion” ). Jaime De Leon Bristol-Myers Squibb Co. IFM Therapeutics Inc. IFM Therapeutics LLC University of Bonn NLR...
BioCentury | Feb 21, 2018
Distillery Techniques

Drug delivery

...Famulok, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany email: m.famulok@uni-bonn.de Hongjiang Li Caris Life Sciences Inc. University of Bonn c-Met...
BioCentury | Jan 19, 2018
Strategy

After amyloid

...the field. An inflammasome target for AD was recently identified by a team from the University of Bonn...
...extracellular environment and further triggers more and more β amyloid aggregation,” said Eicke Latz, a University of Bonn...
...Altos, Calif. Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland Tiaki Therapeutics, Cambridge, Mass. University of Bonn...
BioCentury | Jan 4, 2018
Distillery Therapeutics

Neurology

...Venegas, C. et al. Nature ; published online Dec. 20, 2017 doi:10.1038/nature25158 CONTACT: Michael Heneka, University of Bonn...
BioCentury | Dec 22, 2017
Preclinical News

New inflammasome target for early intervention in AD

...disease, offering an earlier intervention than targeting established amyloid plaques. The study was led by University of Bonn...
...treat chronic inflammatory conditions (see BioCentury Innovations, Aug. 10 ) . Allison Johnson Bristol-Myers Squibb Co. IFM Therapeutics LLC University of Bonn NLR...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Cancer

...Tüting, same affiliation as above email: thomas.tueting@med.ovgu.de CONTACT: Michael Hölzel, University of Bonn, Bonn, Germany email: michael.hoelzel@ukbonn.de Mark Zipkin capmatinib University of Bonn c-Met...
Items per page:
1 - 10 of 71